Lunai Bioworks Inc. (NASDAQ:LNAI) Short Interest Down 86.1% in May

Lunai Bioworks Inc. (NASDAQ:LNAI) was the target of a significant decrease in short interest during the month of May. As of May 29th, there was short interest totaling 345,109 shares, a decrease of 86.1% from the May 14th total of 2,489,634 shares. Currently, 7.7% of the shares of the stock are sold short. Based on an average trading volume of 217,022 shares, the days-to-cover ratio is currently 1.6 days.

Wall Street Analyst Weigh In

A number of research firms recently commented on LNAI. Wall Street Zen raised Lunai Bioworks to a “sell” rating in a research note on Saturday, May 23rd. Weiss Ratings reissued a “sell (e+)” rating on shares of Lunai Bioworks in a research note on Friday, April 10th. One analyst has rated the stock with a Sell rating, Based on data from MarketBeat, the company currently has a consensus rating of “Sell”.

Institutional Trading of Lunai Bioworks

An institutional investor recently bought a new position in Lunai Bioworks stock. Millennium Management LLC purchased a new stake in shares of Lunai Bioworks Inc. (NASDAQ:LNAI) in the 3rd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor purchased 202,629 shares of the company’s stock, valued at approximately $288,000. Millennium Management LLC owned 0.87% of Lunai Bioworks as of its most recent SEC filing. Hedge funds and other institutional investors own 71.41% of the company’s stock.

Lunai Bioworks Price Performance

NASDAQ LNAI traded down $0.03 during trading on Wednesday, hitting $2.26. 24,704 shares of the company’s stock traded hands, compared to its average volume of 1,551,275. The stock has a fifty day moving average of $2.63 and a two-hundred day moving average of $5.07. Lunai Bioworks has a 12-month low of $1.21 and a 12-month high of $33.50. The firm has a market cap of $10.24 million, a P/E ratio of -5.65 and a beta of 0.40.

Lunai Bioworks (NASDAQ:LNAI) last posted its quarterly earnings results on Friday, May 15th. The company reported ($0.80) earnings per share (EPS) for the quarter. The business had revenue of $0.02 million for the quarter.

Lunai Bioworks Company Profile

Enochian Biosciences, Inc, a pre-clinical stage biotechnology company, engages in the research and development of pharmaceutical and biological products for the human treatment of human immunodeficiency virus (HIV), hepatitis B virus (HBV), influenza and coronavirus infections, and cancer. The company’s lead candidate includes ENOB-HV-01 for autologous HIV curative treatment; ENOB-HV-11, a preventative HIV vaccine; ENOB-HV-12, a therapeutic HIV vaccine; and ENOB-HB-01, a coopting HBV polymerase. Its pipeline development products comprise ENOB-DC-11 off the shelf DC vaccine for multiple solid tumors; and ENOB-DC-21, a non-specific vaccine for intraturmoral injection.